Glucagon-like peptide 1 (GLP-1) receptor agonists are transforming the treatment landscape for type 2 diabetes ( T2D) and obesity, in addition to their cardiovascular benefits. These drugs also show promise in managing inflammatory and neurodegenerative diseases, offering a comprehensive approach for patients with multiple comorbidities.<\/p>\n
This multifaceted pharmacological class mimics the action of endogenous GLP-1 and has demonstrated benefits far beyond glycemic control and weight loss. Therefore, it is essential for healthcare professionals to stay updated on the latest evidence.<\/p>\n
Mechanism of Action<\/strong><\/p>\n GLP-1, an incretin hormone secreted by intestinal L cells in response to food intake, enhances glucose-dependent insulin secretion, suppresses glucagon release, and delays gastric emptying, thereby aiding postprandial glucose control. It also acts on the brain to promote satiety and reduce caloric intake. GLP-1 analogs mimic these actions by activating GLP-1 receptors in the pancreas, brain, and gastrointestinal tract.<\/p>\n Glycemic Control<\/strong><\/p>\n The GLP-1 hormone plays a vital role in the regulation of blood sugar levels. Drugs that mimic its action enhance insulin secretion in a glucose-dependent manner and have been shown to effectively lower glycosylated hemoglobin (A1c) levels in patients with T2D.<\/p>\n Studies indicate that GLP-1 agonists can reduce A1c levels by 1%-1.5%, depending on the specific drug and patient population. This reduction is comparable with or even greater than that achieved with basal insulin, providing better glycemic control with a lower risk for hypoglycemia.<\/p>\n Moreover, these medications reduce glucagon secretion during hyperglycemia, decreasing hepatic glucose production and further supporting glycemic control. This advancement has revolutionized T2D treatment.<\/p>\n Weight Loss<\/strong><\/p>\n Beyond glycemic benefits, GLP-1 analogs such as semaglutide have demonstrated exceptional weight loss outcomes, with clinical trials reporting up to 15% body weight reduction.<\/p>\n These drugs act through multiple mechanisms. \u201cAt the brain level, these drugs modulate the hypothalamic appetite centers, promoting satiety and significantly reducing calorie intake,\u201d Sharona Azriel, MD, PhD, an endocrinologist at the Hospital Universitario Infanta Sof\u00eda in Madrid, Spain, and secretary of the Spanish Society for the Study of Obesity<\/a>, told El M\u00e9dico Interactivo, a Medscape Network platform.<\/p>\n This regulation also extends to reward circuits, decreasing the need to seek pleasure from food. As a result, patients treated with these drugs reduce their food and water intake.<\/p>\n Another noteworthy aspect, she added, is the altered perception of food palatability, \u201cAlthough the exact mechanism is not yet fully understood, it has been suggested that GLP-1 analogs could modify preferences for certain types of foods, also contributing to a healthier diet.\u201d<\/p>\n Gastric Emptying<\/strong><\/p>\n At the gastrointestinal level, these drugs slow gastric emptying, resulting in a greater sense of postprandial satiety or fullness. Consequently, the rate at which glucose enters the bloodstream after a meal is reduced, improving postprandial glucose spikes and satiety, which also supports weight loss.<\/p>\n These drugs may also help preserve beta cell function, protecting them against stress and apoptosis. \u201cThis is important for patients with T2D, as progressive beta-cell dysfunction is a key factor in the disease\u2019s development,\u201d she highlighted.<\/p>\n These mechanisms explain why GLP-1 analogs have emerged as an effective therapeutic option approved for treating both T2D and obesity.<\/p>\n Cardiovascular Protection<\/strong><\/p>\n Studies such as SUSTAIN-6<\/a>, SELECT<\/a>, and LEADER<\/a> reveal that GLP-1 analogs such as semaglutide and liraglutide reduce major cardiovascular events. These benefits are independent of weight loss. A 2023 study<\/a> found that semaglutide (2.4 mg) significantly reduced major cardiovascular events, such as heart attack and stroke, in patients with obesity and cardiovascular disease but without diabetes. Its obesity formulation also provides benefits for heart disease prevention and related conditions, including hypertension and sleep apnea.<\/p>\n \u201cThis is particularly interesting because one might think that this benefit could be secondary to weight loss as it reduces the risk of associated complications. However, in this case, various sub-studies have shown that the benefit is independent of whether patients lost more or less than 5% of their weight,\u201d emphasized Azriel.<\/p>\n Anti-Inflammatory Effects<\/strong><\/p>\n Although the exact mechanism for this reduction in cardiovascular risk has not been established, \u201cthese benefits appear to be related to the anti-inflammatory properties of these drugs, which also promote vasodilation and reduce arterial stiffness and oxidative stress. These drugs have a clear antiatherosclerotic effect and a positive impact on postprandial lipid metabolism, helping to reduce the burden of triglycerides and other fats in circulation after food intake,\u201d Azriel explained. This is particularly relevant in patients with dyslipidemia, which is a key factor in the progression of cardiovascular diseases.<\/p>\n In patients with heart failure with preserved ejection fraction, these drugs enhance exercise tolerance and quality of life, as reflected by improved scores on the Quality of Life Scale and fewer hospitalizations for cardiac decompensation.<\/p>\n Joint and Skin Benefits<\/strong><\/p>\n A study published in The New England Journal of Medicine<\/a> found that semaglutide reduces knee osteoarthritis pain more effectively than a placebo. Similarly, animal studies have shown that liraglutide helps alleviate pain from this condition.<\/p>\n In addition to weight loss, which eases joint stress and improves mobility, GLP-1 analogs have anti-inflammatory and immunomodulatory effects that may reduce joint pain and inflammation.<\/p>\n \u201cSimilarly, patients with psoriasis treated with these drugs have shown improvement, suggesting a beneficial impact on chronic inflammatory diseases,\u201d said Azriel. These findings reinforce the hypothesis that GLP-1 analogs may have a therapeutic role in various inflammation-based diseases, opening new avenues for research and clinical possibilities in the coming years.<\/p>\n Renal and Hepatic Benefits<\/strong><\/p>\n These drugs may also have nephroprotective effects<\/a> and the potential to treat metabolic liver diseases. GLP-1 analogs may slow the progression of chronic kidney disease, reduce albuminuria, a key marker of kidney damage, and increase diuresis and natriuresis, which contributes to less overload of the renal system in patients with T2D.<\/p>\n \u201cWhile these effects have been observed in patients with T2D and obesity, specific studies in obese individuals without diabetes are still lacking, but the data suggest they may play a key role in the treatment of chronic kidney disease beyond glycemic control,\u201d Azriel explained.<\/p>\n GLP-1 analogs are being studied for their hepatoprotective effects, reducing the progression of metabolic dysfunction\u2013associated steatohepatitis, a condition characterized by liver inflammation and fibrosis in people with fatty liver disease associated with metabolic dysfunction.<\/p>\n Azriel noted that preclinical studies show patients treated with GLP-1 analogs or tirzepatide<\/a> (a dual glucose-dependent insulinotropic polypeptide and GLP-1 analog) have less liver fibrosis progression, suggesting a hepatoprotective effect on the liver.<\/p>\n Neurodegenerative\u00a0Potential<\/strong><\/p>\n GLP-1 agonists show promise in neurology, as they reduce neuroinflammation, improve neuronal function, and minimize brain damage in diseases such as Alzheimer\u2019s and Parkinson\u2019s.<\/p>\n Currently, multiple phase 3 clinical trials are evaluating the effect of these drugs on neurodegenerative diseases. In Alzheimer\u2019s, they reduce beta-amyloid plaques and enhance cognitive function. In Parkinson\u2019s disease, they protect dopaminergic neurons, slow disease progression, and improve motor function.<\/p>\n Addiction and Psychiatric Disorders<\/strong><\/p>\n GLP-1 analogs modulate the brain\u2019s dopaminergic reward system, reducing cravings for addictive substances such as alcohol and drugs. Studies on semaglutide have revealed a lower incidence of alcohol abuse<\/a> and relapse in individuals with alcohol dependence, likely due to its inhibition of positive reinforcement linked to alcohol consumption.<\/p>\n These effects on the dopaminergic system have also sparked interest in their potential for treating psychiatric disorders such as depression and mood disorders. Clinical trials are underway to determine whether modulating the reward system can improve depressive symptoms in patients with obesity and T2D.<\/p>\n Obstructive sleep apnea is a common condition in individuals with obesity and T2D and is associated with cognitive decline and cardiovascular risk.<\/p>\n